AuroBlog - Aurous Healthcare Clinical Trials blog
APRIL 7, 2024
A drug used to treat diabetes slowed the progression of motor issues associated with Parkinson’s disease, a study published in the New England Journal of Medicine said Wednesday. Parkinson’s is a devastating nervous system disorder affecting 10 million people worldwide, with no current cure.
Fierce Pharma
APRIL 7, 2024
Last year closed with a flurry of big-money biopharma deals. Of the industry’s top 10 acquisitions, six came in the fourth quarter. | Market research by McKinsey found that smaller, strategic M&A deals provide greater shareholder returns than multibillion-dollar acquisitions. Analysts from McKinsey and Project Farma explain why and offer advice on how to optimize deals.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
APRIL 7, 2024
FDA approves earlier use of J&J's BCMA CAR-T therapy Carvykti and BMS' rival Abecma for earlier use in multiple myeloma
Drug Patent Watch
APRIL 7, 2024
Annual Drug Patent Expirations for RELISTOR Relistor is a drug marketed by Salix Pharms and Salix and is included in two NDAs. It is available from one supplier.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
JAMA Internal Medicine
APRIL 7, 2024
This randomized clinical trial seeks to determine whether d-mannose taken for 6 months reduces the proportion of women with recurrent urinary tract infections experiencing a medically attended urinary tract infection.
BioSpace
APRIL 7, 2024
Helix Biostructures offers a full gene-to-structure suite of cryo-EM services that focuses on both quality and fast turnaround/throughput.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
BioSpace
APRIL 7, 2024
Researchers are working to optimize the properties of antibody-drug conjugates in order to maximize clinical efficacy while minimizing the risk of toxicities.
Drug Patent Watch
APRIL 7, 2024
Annual Drug Patent Expirations for ARIKAYCE+KIT Arikayce Kit is a drug marketed by Insmed Inc and is included in one NDA. It is available from one supplier.
BioSpace
APRIL 7, 2024
2024 began with several biopharma players posting positive Phase III data that could mean new market share for the companies and longer survival times and quality of life for patients.
BioSpace
APRIL 7, 2024
With second-generation antibody-drug conjugates, Eli Lilly, Daiichi Sankyo and others look to reduce toxicity and improve the magnitude and duration of response.
Expert insights. Personalized for you.
231 
Let's personalize your content